Actinogen Medical Expands Alzheimer's Drug Trial to US

Actinogen Medical Limited has launched a pivotal phase 2b/3 trial for its Alzheimer’s treatment, Xanamem, marking a significant step forward in the fight against neurological conditions. The trial has now expanded to include the first US participant, with the study being conducted across 25 sites in both the US and Australia. This extensive trial aims to evaluate the efficacy of Xanamem on cognitive and functional measures in patients suffering from Alzheimer's disease. Interim results from the study are expected to be released in 2025, with the final results anticipated in 2026. This expansion underscores Actinogen Medical's commitment to developing innovative treatments for Alzheimer's and other neurological disorders.